Sirnaomics Launches Phase I Clinical Trial of RNAi Therapeutic STP705 in Adults Undergoing Abdominoplasty for Medical Cosmetology Treatment

/PRNewswire/ -- Sirnaomics Ltd. (the "Company" or "Sirnaomics", stock code: 2257.HK), a leading biopharmaceutical company in discovery and development of RNAi...

Related Keywords

China ,United States ,Suzhou ,Jiangsu ,Chinese ,Nigel Yip ,Bunny Lee ,Alexis Feinberg ,Michael Molyneaux ,Patrick Lu ,Drug Administration ,Company Or Sirnaomics ,View Research ,Sirnaomics Ltd ,Chinese National Medical Products Administration ,Financial Office ,Prnewswire Sirnaomics Ltd ,Grand View Research ,Sirnaomics Executive Director ,Executive Director ,Orphan Drug Designation ,Chief Medical Officer ,Media Contact ,Health Care Amp Hospitals ,Medical Pharmaceuticals ,Pharmaceuticals ,Clinical Trials Amp Medical Discoveries ,New Products Amp Services ,